LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Search

Design Therapeutics Inc

Gesloten

10.98 -1.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.62

Max

11.18

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.6M

-18M

EPS

-0.29

Werknemers

54

EBITDA

-1.5M

-20M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+76.58% upside

Dividenden

By Dow Jones

Volgende Winsten

5 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

98M

898M

Vorige openingsprijs

12.42

Vorige sluitingsprijs

10.98

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 mei 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mei 2026, 16:49 UTC

Winsten

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mei 2026, 16:26 UTC

Belangrijke Marktbewegers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mei 2026, 23:51 UTC

Marktinformatie

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mei 2026, 23:37 UTC

Winsten

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 mei 2026, 23:30 UTC

Marktinformatie

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mei 2026, 22:33 UTC

Acquisities, Fusies, Overnames

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mei 2026, 21:53 UTC

Winsten

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mei 2026, 21:02 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mei 2026, 20:55 UTC

Winsten

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mei 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mei 2026, 20:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 mei 2026, 20:20 UTC

Marktinformatie

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Adj EPS 3c >BULL

21 mei 2026, 20:20 UTC

Winsten

Webull 1Q Rev $159.9M >BULL

21 mei 2026, 20:18 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mei 2026, 20:18 UTC

Winsten

Webull 1Q Loss/Shr 4c

21 mei 2026, 19:43 UTC

Marktinformatie

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mei 2026, 18:58 UTC

Winsten

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mei 2026, 18:15 UTC

Marktinformatie

Gold Higher For Second Consecutive Day -- Market Talk

21 mei 2026, 17:40 UTC

Marktinformatie

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mei 2026, 17:04 UTC

Marktinformatie

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mei 2026, 17:01 UTC

Winsten

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mei 2026, 16:20 UTC

Marktinformatie
Winsten

Stellantis Targets Distant but Constructive -- Market Talk

21 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

76.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.6 USD  76.58%

Hoogste 22 USD

Laagste 15 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat